Immunotherapy makes breakthrough in breast cancer

In the Impassion 130 study, triple-negative breast cancer patients treated with immunotherapy and chemotherapy survived 7.2 months without the disease progressing, compared with 5.5 months in the chemotherapy- only group.
In the Impassion 130 study, triple-negative breast cancer patients treated with immunotherapy and chemotherapy survived 7.2 months without the disease progressing, compared with 5.5 months in the chemotherapy- only group.PHOTO: ISTOCKPHOTO

Global study shows immunotherapy, combined with chemotherapy, can help to extend lives of patients with aggressive breast cancer

News that combining chemotherapy with immunotherapy can help extend the lifespan of triple-negative breast cancer patients offers hope for those inflicted with this aggressive and hard-to-treat cancer.

It is a breakthrough for immunotherapy as breast cancer was thought to be unresponsive to the body's immune system.

Please or to continue reading the full article. Learn more about ST PREMIUM.

Enjoy unlimited access to ST's best work

  • Exclusive stories and features on multiple devices
  • In-depth analyses and opinion pieces
  • ePaper and award-winning multimedia content
A version of this article appeared in the print edition of The Straits Times on November 05, 2018, with the headline 'Immunotherapy makes breakthrough in breast cancer'. Print Edition | Subscribe